Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Journal
The Lancet Neurology
Journal Volume
20
Journal Issue
1
Pages
49
Date Issued
2021-01
Author(s)
Adams D.
Polydefkis M.
González-Duarte A.
Wixner J.
Kristen A.V.
Schmidt H.H.
Berk J.L.
Losada López I.A.
Dispenzieri A.
Quan D.
Conceição I.M.
Stephant M.
Echaniz-Laguna A.
Becquemont L.
Beaudonnet G.
Algalarrondo V.
Eliahou L.
Signate A.
Berthelot E.
Inamo J.
Vervoitte L.
Slama M.S.
Focseneanu C.
Gendre T.
Arrouasse R.
Ayache S.S.
Ernande L.
Le Corvoisier P.
Salhi H.
Choumert A.
Ehinger V.
Ruiz J.
Gillmore J.D.
Charlin C.
Megelin T.
Brannagan III T.H.
Fayerman R.
Kim A.
Paras A.
Gonzalez L.J.
Tsang S.
Wajnsztajn F.
Shije J.
Kyriakides T.
Ulane C.
Kleyman I.
Weimer L.
Cioroiu C.
Lambrianides S.
Abu-Manneh R.
Zamba-Papanicolaou E.
Agathangelou P.
Leonidou E.
Tada S.
Ajroud-Driss S.
Fujita A.
Nagai M.
Ando R.
Hosokawa Y.
Yamanishi Y.
Overcash J.S.
Giardino E.
Boyer L.
Dang L.
Le A.
Waddington-Cruz M.
Nguyen T.
Giang L.
Sellers P.
Tran L.
Truong N.
Vinas M.
Hrkman N.
Miller S.
Nguyen D.
Smith A.
Mezei M.M.
Pu H.
Li S.
Vuong T.
Dioso H.
Green S.
Lee K.
Chu H.
Waters M.
Coskun D.J.
Zepeda K.A.
Planté-Bordeneuve V.
O'Riordan W.
Obici L.
Cortese A.
Lozza A.
Merlini G.
Rosti V.
Sabatelli M.
Bisogni G.
Bernardo D.
Luigetti M.
Attarian S.
Di Paolantonio A.
Guglielmino V.
Romano A.
Nienhuis H.
Bulthuis-Kuiper J.
Gerk O.
Ulbricht H.
Taylor L.
Meyle E.
Kleinschmidt N.
Mauricio E.
Meyrath D.
Noe-Schwenn S.
Meng U.
Bauer R.
aus dem Siepen F.
Hein S.
Takahashi T.
Oshita T.
Koujin Y.
Neshige S.
Brannagan T.H.
Nezu T.
Segawa A.
Ueno H.
Morino H.
Campistol J.M.
Rodas Marin L.M.
Blasco Pelicano J.M.
Dávila L.G.
Palacios M.
Pytel Cordoba V.
III, Ueda M.
Guerrero Sola A.
Horga A.
García Feijoo J.
Perez de Isla L.
Marques Júnior W.
Moscardini M.
Litcanov D.C.
Viera Lima A.F.
Rodrigues L.
Marques Coutinho B.
Aldinc E.
Moreira C.L.
Daccach Marques V.
Munoz Beamud F.
Gragera Martínez Á.
Borrachero C.
Cisneros Barroso E.
Rodríguez Rodríguez A.
Sanz M.
Rigo Oliver E.
González Moreno J.
Wang J.J.
Gamez Martinez J.M.
Descals C.
Uson M.
Jose Vega F.
Figuerola A.
Montala C.
Dias da Silva M.
Gervais de Santa Rosa R.
Pinto L.F.
Pinto M.V.
White M.T.
Cardoso Berensztejn A.
Barroso F.
Lautre A.
Orellana L.G.
González-Duarte Briseño M.A.
Cárdenas-Soto K.
Jiménez López B.P.
Pérez-Castañeda S.L.
Cantú Brito C.G.
Rivera de la Parra D.
Vest J.
Hernandez Reyes J.P.
del Mar Saniger Alba M.
Criollo Mora E.
Parman Y.
Rezzan K.J.
Sahin E.
Serbest N.G.
Durmus H.
Cakar A.
Tugal Tutkun N.I.
Berber E.
Karamursel S.
Elitok A.
Sirin Inan N.G.
Altinkurt E.
Ye J.
Allen A.C.
Chaudhry V.
Jarrett R.
Bressler N.
Burks K.L.
Sweetser M.T.
Liu Q.
Khoshnoodi M.
Judge D.P.
Vista G.
Shah S.M.
Hamaguchi H.
Oda J.
Fukase E.
Taniguchi I.
Oda T.
Coelho T.
Endo H.
Shimomura M.
Katanazaka K.
Koto S.
Nakano T.
Scheid C.
Zueiter A.
Pester L.
Walter D.
Özdemir B.
Vita G.
Frenzel L.F.
Holtick U.
Oh J.
Kim H.J.
Shin H.J.
Choi K.
Yamashita T.
Masuda T.
Misumi Y.
Ueda A.
Rizzo V.
Nakahara K.
Yorita A.
Tsuruhisa S.
Taniwaki T.
Harada M.
Moritaka T.
Sakurada N.
Mauricio E.A.
Baskin A.
Dimberg E.
Russo M.
Fonder A.
Hobbs M.
Russell S.J.
Dyck P.
Gonsalves W.
Leung N.
Witzig T.E.
Zeldenrust S.R.
Hwa L.
Kapoor P.
Mazzeo A.
Kumar S.K.
Lin Y.
Lust J.A.
Rajkumar V.S.
Dingli D.
Gertz M.A.
Go R.
Hayman S.R.
Dalia S.
Carrillo E.
Gentile L.
Gorevic P.
Mason G.
Yang C.-C.
Ajroud-Driss S.A.-D.
Brueckner C.
Casey P.
Joslin B.C.
Freimer M.
Sankey A.
Kenepp A.
Heintzman S.
LoRusso S.
Hokezu Y.
Kim B.-J.
Kim J.
Lazzari V.
Lee G.Y.
Cho E.B.
Jeon E.-S.
Min J.-H.
Seok J.M.
Lee H.L.
Park J.H.
Sekijima Y.
Miyazawa C.
Kato N.
Wiesman J.
Kishida D.
Hineno A.
Kodaira M.
Yoshinaga T.
Miyahara T.
Imai A.
Matsumoto K.
Lin K.-P.
Lee Y.-C.
Falk M.
DeLong D.
Pilebro B.
Suhr O.
Lindqvist P.
Soderberg K.
Pedrosa-Domellöf F.
Anan I.
Nordh E.
Tournev I.
Zhelyazkova-Glaveeva S.
Cherneva Z.
Victory J.
Sarafov S.
Chamova T.
Cherninkova-Gopina S.
Friebel F.
Zibert A.
Mihailovic N.
Schubert F.
Vorona E.
Lahme L.
Huesing-Kabar A.
Dalton J.
Schilling M.
Kabar I.
Martinez-Naharro A.
Chacko L.
Cohen O.
Law S.
Rezk T.
Lachmann H.J.
Blume B.
Dixon S.
May J.
Low S.C.
Chan S.L.
Lim H.E.L.
Goh K.J.
Kraus D.
Jack K.
Lopate G.
Zwijack B.
Florence J.
Sommerville R.B.
Gilmore C.
Stewart G.
Ryder J.
Mekhael L.
Taylor M.
Suan D.
Wells K.
Stone P.
Itoya A.
Owusu-Sekyere M.
Thai D.
Diallo S.
Chahine I.
Pedrosa S.
Do T.H.T.
patisiran Global OLE study group
Delmont E.
Pouget J.
Verschueren A.
Grapperon A.-M.
Campana-Salort E.
Lopes A.
Lamas F.
Neves C.
Castro J.
Pereira P.
Castro I.
Franco A.
Santos M.O.
de Azevedo Coutinho C.
Falcao de Campos C.
Hipólito Reis A.
Correia N.
Perez J.M.
Martins da Silva A.
Alves C.
Cardoso M.
Valdrez K.
Monte J.R.
Pessoa B.
Guimaraes N.
Freitas M.
Ramalho J.
Ferreira N.
Kuzume D.
Tard C.
Waucquier N.
Rougeaux I.
Brice S.
Kasprzyk E.
Elrezzi E.
Meguig S.
Hachulla E.
Gauvain C.
Migaud-Chervy M.-C.
Deplanque D.
Jozefowicz E.
Lebellec L.
Balaya-Gouraya L.
Jehan Lacour N.
Bournane H.
Martin N.
Elabed M.
Sacko N.
Boubrit Y.
Gaouar A.
Rakotondratafika F.
Théaudin-Saliou M.
Cauquil-Michon C.
Labeyrie C.
Not A.
Al-Salameh A.
Lecoq A.-L.
Abstract
Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran. Alnylam Pharmaceuticals.
SDGs
Type
journal article